PRO-101: study design and interim results from a hybrid Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in ALS (ALS-MND 2024) - Nov 8, 2024 - Abstract #CLT-10; Pres time: Dec 7, 2024; 05:30 PM - 07:00 PM; Location: Poster Hall at the Palais de Congres Montreal; 517b/c; "In healthy volunteers, no serious adverse events or abnormalities in any safety assessments were identified. Plasma levels of prosetin increased in a predictable manner, with low intra-subject variability and clear separation between doses. A growing body of evidence links MAP4K inhibition to neuronal survival in ALS (3,4), making it an attractive target for therapeutic intervention."
Clinical • P1 data • PK/PD data
|
|
E. Fleming 1; A. Ruby 1; E. Lowry 4; H. Williams 1; A. Zask 3; B. Stockwell 3; H. Wichterle 2
|